Cornelis Alexander Izeboud
Director/Board Member bij TME PHARMA N.V.
Oorsprong van het eerstegraads netwerk van Cornelis Alexander Izeboud
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 11 | |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.
11
| Holding Company | Miscellaneous Commercial Services | 11 |
NOMAD Bioscience GmbH
NOMAD Bioscience GmbH BiotechnologyHealth Technology NOMAD Bioscience GmbH provides research and development services in the field of biomaterials. It holds interests in the biotechnologies, biogas, biofuel, and medicinal products. The company was founded by Yuri Gleba in 2008 and is headquartered in Munich, Germany.
1
| Private Company | Biotechnology | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Cornelis Alexander Izeboud via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
TRANSLATE BIO, INC. | Biotechnology | Director/Board Member | |
Kreos Capital Management (UK) Ltd.
Kreos Capital Management (UK) Ltd. Investment ManagersFinance Kreos Capital Management (UK) Ltd (Kreos Capital) is a private equity firm founded in 1998. The firm is headquartered in London with additional offices in Israel, Sweden, Jersey and Luxembourg. | Investment Managers | Private Equity Investor | |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer | |
University of Wisconsin | College/University | Undergraduate Degree Undergraduate Degree | |
INSEAD | College/University | Masters Business Admin Masters Business Admin | |
University of California San Diego | College/University | Doctorate Degree | |
University of Utrecht | College/University | Graduate Degree Doctorate Degree | |
Sapienza University of Rome | College/University | Doctorate Degree | |
Stichting Publieke Private Samenwerking Versterking
Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
IMPLANET SA | Medical Specialties | Director/Board Member | |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member | |
Canbex Therapeutics Ltd.
Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Caerus Consulting AS
Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Pharmaceuticals: Major | Director/Board Member | |
INKEF Capital BV
INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor Private Equity Investor | |
ISOFOL MEDICAL AB | Pharmaceuticals: Major | Director/Board Member | |
Vesalius Biocapital II SA SICAR
Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Investment Managers | Director/Board Member | |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
EUROBIO SCIENTIFIC | Medical Specialties | Corporate Officer/Principal | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chairman | |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Biotechnology | Director/Board Member | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Calypso Biotech SA
Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Genkyotex Innovation SAS
Genkyotex Innovation SAS BiotechnologyHealth Technology Part of Calliditas Therapeutics AB, Genkyotex Innovation SAS engages in research and development of biotechnology. The private company is based in Saint Julien-en-Genevois, France. | Biotechnology | Director/Board Member | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Director/Board Member | |
Escalier Biosciences BV
Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member | |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Founder Founder | |
Vesalius Biocapital Iii Partners SARL | Director/Board Member | ||
Vesalius Biocapital Iii SCA Sicar | Director/Board Member | ||
Vesalius Biocapital Iii Investments SA Sicar | Director/Board Member | ||
Vesalius Biocapital Iii Portugal SARL | Director/Board Member | ||
Genase Therapeutics BV
Genase Therapeutics BV Pharmaceuticals: MajorHealth Technology Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
TigaTx BV
TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that specializes in research and development in the field of health nutrition. The company is based in Utrecht, Netherlands and was founded in 2020 by Jeanette Leusen. | Miscellaneous Commercial Services | Director/Board Member | |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member | |
Vesalius Biocapital III CMF UG | Director/Board Member | ||
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Biotechnology | Director/Board Member | |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
Nederland | 14 |
Verenigde Staten | 9 |
Frankrijk | 7 |
Zwitserland | 6 |
Luxemburg | 6 |
Sectoraal
Health Technology | 30 |
Consumer Services | 6 |
Finance | 5 |
Commercial Services | 5 |
Miscellaneous | 2 |
Operationeel
Director/Board Member | 132 |
Corporate Officer/Principal | 26 |
Director of Finance/CFO | 24 |
Chairman | 23 |
Chief Executive Officer | 22 |
Sterkste connecties
Insiders | |
---|---|
Stéphane Verdood | 32 |
Stephan Christgau | 29 |
Joseph deBethizy | 29 |
Roel Bulthuis | 29 |
Gregory Weaver | 22 |
Edward van Wezel | 20 |
Philippe Dro | 18 |
Bertram Köhler | 13 |
Aram Andrew Mangasarian | 11 |
Alexandra Glucksmann | 11 |
Susan Coles | 10 |
Bryan Jennings | 10 |
Michael Wacker | 7 |
Martine van Vugt | 7 |
Maurizio PetitBon | 6 |
- Beurs
- Insiders
- Cornelis Alexander Izeboud
- Bedrijfsconnecties